Interleukin‐6 serum levels in patients with gynecological tumors

Scambia, Giovanni; Testa, Ugo; Panici, Pierluigi Bendetti; Martucci, Robert; Foti, E; Petrini, Marina; Amoroso, Mariangela; Masciullo, Valeria; Peschle, Cesare; Mancuso, Stefano

doi:10.1002/ijc.2910570305

Cited by 86 publications

(66 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Relations between psychosocial factors and cancer prognosis, survival, and recurrence have previously been documented, [53][54][55][56][57] and IL-6 has been linked to prognosis, survival, recurrence, and effectiveness of treatment. 10,11,15 IL-6 may, therefore, be one pathway by which psychosocial factors such as depression and social support could influence disease outcomes in ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, higher levels of IL-6 have been related to larger tumors, faster tumor progression, decreased effectiveness of chemotherapy, poorer clinical disease status, relapse, and shorter survival. 10,11,15,16 IL-6 is responsive to behavioral factors including stress, depression, and social support. Increased levels of IL-6 have been documented in rats following electrical shock to the foot, restraint, and conditioned aversive stimuli stressors.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Psychosocial factors and interleukin‐6 among women with advanced ovarian cancer

Costanzo¹,

Lutgendorf²,

Sood³

et al. 2005

Cancer

192

120

View full text Add to dashboard Cite

Objective Amyotrophic lateral sclerosis (ALS) is a common, fatal motor neuron disorder with no effective treatment. Approximately 10% of cases are familial ALS (FALS), and the most common genetic abnormality is superoxide dismutase‐1 (SOD1) mutations. Most ALS research in the past decade has focused on the neurotoxicity of mutant SOD1, and this knowledge has directed therapeutic strategies. We recently identified TDP‐43 as the major pathological protein in sporadic ALS. In this study, we investigated TDP‐43 in a larger series of ALS cases (n = 111), including familial cases with and without SOD1 mutations. Methods Ubiquitin and TDP‐43 immunohistochemistry was performed on postmortem tissue from sporadic ALS (n = 59), ALS with SOD1 mutations (n = 15), SOD‐1–negative FALS (n = 11), and ALS with dementia (n = 26). Biochemical analysis was performed on representative cases from each group. Results All cases of sporadic ALS, ALS with dementia, and SOD1‐negative FALS had neuronal and glial inclusions that were immunoreactive for both ubiquitin and TDP‐43. Cases with SOD1 mutations had ubiquitin‐positive neuronal inclusions; however, no cases were immunoreactive for TDP‐43. Biochemical analysis of postmortem tissue from sporadic ALS and SOD1‐negative FALS demonstrated pathological forms of TDP‐43 that were absent in cases with SOD1 mutations. Interpretation These findings implicate pathological TDP‐43 in the pathogenesis of sporadic ALS. In contrast, the absence of pathological TDP‐43 in cases with SOD1 mutations implies that motor neuron degeneration in these cases may result from a different mechanism, and that cases with SOD1 mutations may not be the familial counterpart of sporadic ALS. Ann Neurol 2007;61:427–434

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Psychosocial factors and interleukin‐6 among women with advanced ovarian cancer

Costanzo¹,

Lutgendorf²,

Sood³

et al. 2005

Cancer

192

120

View full text Add to dashboard Cite

show abstract

“…Higher serum IL6 levels has been associated with an increased tumor burden and higher volume of ascites, faster tumor progression, decreased effectiveness of chemotherapy, worse clinical disease status, increased relapse, and impaired survival in ovarian carcinoma [7,8,9,10,11]. Ovarian cancer cells produce significant levels of IL6 and express the soluble IL6 receptor (sIL-6R) [12].…”

Section: Discussionmentioning

confidence: 99%

“…We PCR-amplified the IL6 -174 polymorphism as previously described [8]. The amplicon was purified and sequenced using Big Dye terminator chemistry (Applied Biosystems, Foster City, CA) and an ABI 3100 DNA sequence detection system (Applied Biosystems).…”

Section: Methodsmentioning

confidence: 99%

Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma

Garg

Wollan

Galic

et al. 2006

Gynecologic Oncology

View full text Add to dashboard Cite

Objectives-The IL6 -174 promoter polymorphism impacts serum cytokine levels through transcriptional regulation. The objective of our study was to determine if -174 IL6 genotype influences survival in ovarian cancer.Methods-The IL6 -174 polymorphism was assessed by direct DNA sequencing in lymphocyte DNA from 160 women with invasive ovarian, or peritoneal cancer patients. IL6 levels were measured in ascites and plasma in a subset of cases using colorimetric sandwich ELISA procedure. Overall survival was calculated according to the method of Kaplan and Meier. Cox regression analysis was used to evaluate the significance of individual variables in multivariate analysis. Chi-square or Fishers Exact was used to assess the significance of contingency tables.Results-The IL6 -174 genotype frequencies of CC (19%), CG (50%), and GG (31%) were in Hardy-Weinberg equilibrium and were similar to published frequencies in Caucasian controls. There were no associations with IL6 -174 genotype and age, stage or optimal cytoreduction. Stage had a significant impact on survival (p=0.003). The IL6 -174 GG genotype was significantly associated with longer overall survival (median 131 months) compared to CC or CG (median 28 months, p=0.0007). In cox regression analysis using the covariates genotype (p=0.006) and stage (p=0.02), both were independently significant. Furthermore, there was no association found between IL6 levels in ascites or plasma, and genotype, stage, or overall survival.Conclusions-The IL6 -174 GG genotype has a strong, independent, and favorable impact on survival for women with ovarian, and peritoneal carcinoma.

show abstract

“…Increased serum levels of IL-6, found in a large percentage of patients, correlated with tumor size and grade, and IL-6 pretreatment serum levels correlated as an independent factor with prognosis, similarly as in many solid tumors, including renal cancer, 52 colorectal cancer, 19,53 lung cancer, 54 gynecological cancers 55 and melanoma. 25 Tamm et al have shown that IL-6 may directly promote tumor cells motility and invasion.…”

Section: Cytokine Serum Levels During Follow-upmentioning

confidence: 99%

Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Rutkowski

Kamińska

Kowalska

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

We investigated the correlations between serum levels of selected proinflammatory, hematopoietic and angiogenic cytokines and soluble cytokine receptors with the clinicopathological features and prognosis in soft tissue sarcoma patients. Serum levels of 9 cytokines (TNF␣, IL-1ra, IL-6, IL-8, IL-10, M-CSF, G-CSF, VEGF, bFGF) and 4 free cytokine receptors (sIL-2R␣, sIL-6R, TNFRI, TNFRII) were measured by means of an enzyme-linked immunoadsorbent assay kit in 156 soft tissue sarcoma patients before the treatment and in 50 healthy controls. Serum levels of 10 cytokines and cytokine receptors were also assayed during patients' follow-up after the treatment. Significantly elevated pretreatment serum levels of 11/13 cytokines and cytokine receptors were found in sarcoma patients, as compared to healthy controls.

show abstract

Interleukin‐6 serum levels in patients with gynecological tumors

Cited by 86 publications

References 16 publications

Psychosocial factors and interleukin‐6 among women with advanced ovarian cancer

Psychosocial factors and interleukin‐6 among women with advanced ovarian cancer

Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma

Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Contact Info

Product

Resources

About